Xbrane Biopharma
0.214 SEK -1.39%2 investors are following this company
Xbrane Biopharma is a biotechnology company. The company specializes in research and development of drugs for the treatment of critical illnesses. Today, the business is focused on research in microspherical technology and in the development of protein molecules. The products are used in the treatment of prostate cancer and endometriosis, as well as in rare and serious eye diseases. The company's head office is located in Solna.
Revenue
238.73M
EBIT %
-134.95 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
XBRANE
Daily low / high price
0.213 / 0.228
SEK
Market cap
326.54M SEK
Turnover
2.52M SEK
Volume
12M
Latest videos
Financial calendar
General meeting
2024-05-02
Interim report
2024-05-16
Interim report
2024-07-17
Interim report
2024-10-24
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Ashkan Pouya | 11.0 % | 11.0 % |
Bengt Göran Westman | 8.3 % | 8.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Finansinspektionen: Flaggningsmeddelande i Xbrane Biopharma AB
Xbrane Biopharma, Pressconference, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools